The quarterly earnings season has seen roughly 86% of firms reported results that have topped analysts’ estimates. S&P 500 earnings growth for the period is seen rising 9.3% versus a year ago, on ...

Erik Gershwind to Retire as CEO and Remain on Board as Non-Executive Vice Chair Martina McIsaac to Succeed Erik Gershwind as CEO MELVILLE, NY AND DAVIDSON, NC / ACCESS Newswire / October 23, 2025 / ...

Today’s ACT Brief explores how eConsent is modernizing participant engagement, highlights new data on global representation in breast cancer trials, and examines Moderna’s decision to halt its Phase ...

A bipartisan group of senators is working to draft legislation to reform a fast-growing hospital drug discount program designed to help low-income patients.

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event – Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025. The ...

New findings highlight Telomir-1’s impact on CASP8 and GSTP1, two critical genes that regulate cell death and glutathione-based detoxification pathways often disrupted in cancer. MIAMI, FLORIDA / ...

Moderna announced in October 2025 that it will discontinue development of its investigational cytomegalovirus (CMV) vaccine, ...

Founder of Peloza Spine joined national healthcare leaders to discuss physician-led innovation and operational excellence in ...

PHOENIX, ARIZONA / ACCESS Newswire / October 22, 2025 / AeroGuard Flight Training Center, a leading provider of flight ...

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

Moderna’s highly touted cytomegalovirus vaccine — long billed as its next big win after its Covid-19 shot — failed a Phase 3 ...

US biotech Moderna (Nasdaq: MRNA) is discontinuing its once-promising vaccine for congenital cytomegalovirus (CMV) after the shot failed to prevent primary infection in healthy women during a Phase ...